Fig. 1 · Structure

Documents & Downloads

Morin hydrate

Cat. No. A10605 CAS 6202-27-3
Morin hydrate is a chemical compound. Morin can be used to test for the presence of aluminum or tin in a solution, since it forms characteristically fluorescent coordination complexes with them.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Morin hydrate suppresses human IAPP fibril formation in cell-free experiments supported by TEM and light scattering. Morphological disruption of preformed fibers was also observed after compound addition. Residual aggregate material and interference with thioflavin-T assays limit interpretation; fluorescence loss alone does not establish fibril removal. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 100 μM Inhibition of MPG in human A549 cell extracts at 50 to 300 uM using 1,N6 ethenoadenine containing 32P-labeled duplex oligonucleotide substrates by gel-based excision activity assay [PMID: 25650313]
HeLa IC50 200 μM Inhibition of MPG in human HeLa cell extracts at 50 to 300 uM using 1,N6 ethenoadenine containing 32P-labeled duplex oligonucleotide substrates by gel-based excision activity assay [PMID: 25650313]

In Vitro Studies

In washed human platelets, morin hydrate inhibited collagen-induced aggregation with a reported approximate IC50 of 40 μM. Aggregation triggered by thrombin, U46619 or arachidonic acid was not inhibited at the tested 20–80 μM concentrations. This response is specific to the tested agonist conditions. [2]

Suppression of human IAPP aggregation with orthogonal assay validation

Biochemical assay · Cell-free synthetic human islet amyloid polypeptide (IAPP), 32 μM [1]

Morin hydrate reduced fibrillar material in TEM concentration comparisons and suppressed the rise in right-angle light scattering at fivefold molar excess. Residual thin or short structures and amorphous material remained visible; the evidence supports inhibition of fibril formation under these conditions, not complete removal of all aggregates. Myricetin retained fibrils despite low thioflavin-T fluorescence, demonstrating a false-positive risk for fluorescence-only screens.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fibrillar morphology compared with IAPP alonequalitative TEM result Fewer/thinner fibrillar structures at 1:1 and 1:2; short structures and amorphous aggregates at 1:5 and 1:10.[1]
Aggregation signal with orthogonal morphology checkright-angle light scattering No increase in light-scattering signal with fivefold morin hydrate over the plotted interval; IAPP alone and IAPP plus myricetin increased.[1]
Myricetin comparator reveals thioflavin-T assay interferenceassay-specificity control Low thioflavin-T signal coexisted with amyloid fibers in the myricetin condition.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Morin hydrate 32–320 μM with 32 μM IAPP (1:1 to 1:10); light-scattering validation used 160 μM morin hydrate (fivefold excess).
Exposure duration
TEM concentration series: 48 h; light scattering with TEM sampling at 42 h.
Method
Co-incubation from time zero at 25°C in 20 mM Tris-HCl, pH 7.4.
Vehicle
0.25% DMSO (v/v).
Reported limits
No IC50 was established. TEM sampling is qualitative; light-scattering caption reports three separate measurements per sample, without establishing three independently prepared biological samples.
Methods and source locations

Compound reported in the paper: Morin hydrate; Compound label in the paper: Morin hydrate

Reported effects of morin hydrate in this experimental model; no validation of an Adooq lot or conversion to anhydrous morin.

Results, inhibition and assay-interference subsections; Figures 2, 4, 5; Materials and Methods

Fibrillar morphology compared with IAPP alone: TEM at 48 h; same IAPP concentration and reported solvent across conditions. — Results, inhibition subsection; Figure 4A–E and caption

Aggregation signal with orthogonal morphology check: 500 nm; three separate measurements per sample; error bars are SD at each point; TEM sampled at 42 h. Sparse residual structures are visible in Figure 5C. — Results; Figure 5A–D and caption; Right-angle light scattering method

Myricetin comparator reveals thioflavin-T assay interference: Thioflavin-T kinetics and end-point TEM, IAPP with or without equimolar myricetin. — Results, Hydroxyflavones can interfere; Figure 2A–C and caption

Morphological disruption of preformed IAPP fibers

Biochemical assay · Cell-free preformed human IAPP amyloid, 32 μM IAPP [1]

After morin hydrate was added to preformed fibers, sampled TEM fields at 1–6 h showed loss of the dense long-fiber networks present immediately before addition, with residual nonfibrillar material. Thioflavin-T was used to establish that fibers had reached the plateau before treatment, not to quantify disassembly kinetics.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Morphology of preformed fibers after compound additionqualitative TEM result Dense fibers before addition; no long fibers detected in sampled TEM images 1–6 h after addition.[1]

Literature-Reported Treatment Conditions

Treatment concentration
160 μM morin hydrate added to 32 μM IAPP (fivefold excess).
Exposure duration
Added approximately 45 h after initiation of fiber formation; TEM at 1, 2, 4 and 6 h after addition.
Method
Addition to preformed fibers at 25°C, 20 mM Tris-HCl, pH 7.4.
Vehicle
0.5% DMSO (v/v), as specified in Figure 6 caption.
Reported limits
Figure 6 provides a before-addition comparison but no time-matched vehicle-only post-addition TEM series. No quantitative disaggregation rate, IC50 or cellular protection endpoint.
Methods and source locations

Compound reported in the paper: Morin hydrate; Compound label in the paper: Morin hydrate

Reported effects of morin hydrate in this experimental model; no validation of an Adooq lot or conversion to anhydrous morin.

Results, disaggregation subsection; Figure 6; Amyloid disaggregation experiments method

Morphology of preformed fibers after compound addition: TEM; 100 nm scale bars; visual result does not establish soluble monomer recovery or biological safety. — Results, Morin hydrate disaggregates IAPP amyloid fibers; Figure 6B–F and caption

Agonist-dependent inhibition of washed human platelet aggregation

Cell-based study · Washed platelets from adult human volunteers; 3.6 × 10^8 cells/mL [2]

Morin hydrate inhibited collagen-stimulated aggregation with a reported approximate IC50 of 40 μM. At the tested concentrations, aggregation induced by thrombin, U46619 or arachidonic acid was not inhibited. These are ex vivo human platelet observations, not a clinical trial or an animal experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Collagen-induced washed human platelet aggregationIC50 approximately 40 μM[2]
Aggregation induced by thrombin, U46619 and arachidonic acidagonist-specific response No inhibition reported for these three agonists at 20, 50 or 80 μM morin hydrate.[2]

Literature-Reported Treatment Conditions

Treatment concentration
20, 50 and 80 μM morin hydrate.
Exposure duration
3 min preincubation; aggregation evaluated after 6 min reaction.
Method
Lumi-aggregometry; collagen 1 μg/mL, thrombin 0.01 U/mL, U46619 1 μM or arachidonic acid 60 μM.
Vehicle
Isovolumetric 0.1% DMSO control.
Reported limits
Figure 1 reports n = 4 and means ± SEM; whether n denotes independent donors is not specified in the reviewed text. IC50 is approximate, reported in Results rather than calculated here.
Methods and source locations

Compound reported in the paper: Morin hydrate; Compound label in the paper: MH

Reported effects of morin hydrate in this experimental model; no validation of an Adooq lot or conversion to anhydrous morin.

Results 2.1; Figure 1A–C; Methods 4.1–4.2

Collagen-induced washed human platelet aggregation: Light-transmission aggregation relative to individual untreated control; collagen 1 μg/mL; n = 4, means ± SEM for Figure 1. — Results 2.1; Figure 1B,C; Methods 4.2

Aggregation induced by thrombin, U46619 and arachidonic acid: Same aggregation comparison with solvent controls; thrombin 0.01 U/mL, U46619 1 μM and arachidonic acid 60 μM. — Results 2.1; Figure 1B,C and caption

In Vivo Studies

In male C57BL/6 mice, oral morin hydrate at 50 mg/kg once daily for five days before acute chemical liver injury reduced serum ALT/AST and histological necrosis compared with vehicle pretreatment. Residual injury remained. The experiment evaluates prevention, with outcomes measured 24 h after challenge. [3]

Preventive morin hydrate treatment in acute chemical liver injury

Animal study · Male C57BL/6 mice, 6–8 weeks, 22–25 g; four randomized groups, eight mice assigned per group; single reported 1 ml/kg CCl4 (1:1 v/v in olive oil), intraperitoneally [3]

Five-day morin hydrate pretreatment reduced serum ALT/AST and histological necrosis after acute chemical liver injury relative to vehicle pretreatment. It did not normalize every injury marker, and morin hydrate alone did not significantly alter liver enzymes in the oil-control comparison. This is a preventive mouse experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum ALT and AST after liver injuryqualitative group difference Both lower with morin hydrate pretreatment than injury plus vehicle (Figure 1C: P < 0.001); morin hydrate / oil versus vehicle / oil: NS.[3]
Hepatic necrosishistological necrosis score Lower necrosis score after morin hydrate pretreatment than injury plus vehicle (P < 0.001); residual necrosis remained.[3]

Conditions shared by the study groups

Route
Oral gavage for morin hydrate or its DMSO vehicle; intraperitoneal CCl4 or olive-oil challenge.
Frequency
Once daily
Treatment course
5 consecutive days before challenge; assessment 24 h after challenge.
Vehicle
DMSO for morin hydrate; olive oil for challenge control. Final DMSO concentration and gavage volume not specified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle / oil
Equal-volume DMSO and olive oil controls.
Normal reference group.Low serum ALT/AST and little necrosis.[3]
Morin hydrate / oil
Morin hydrate 50 mg/kg; olive oil challenge control.
Vehicle / oil.No significant change in liver enzymes versus vehicle / oil in Figure 1C.[3]
Vehicle / liver injury
DMSO pretreatment; single reported 1 ml/kg CCl4 (1:1 v/v in olive oil).
Vehicle / oil.Serum ALT/AST and histological necrosis increased.[3]
Morin hydrate / liver injury
Morin hydrate 50 mg/kg; single reported 1 ml/kg CCl4 (1:1 v/v in olive oil).
Vehicle / liver injury.Lower serum ALT/AST and necrosis score; residual injury remained.[3]
Vehicle / oil
Model: Male C57BL/6 mice, 6–8 weeks, 22–25 g
Reported limits: No pharmacokinetic or therapeutic post-injury dosing evaluation; outcome sample sizes differ from randomized group size.
Morin hydrate / oil
Model: Male C57BL/6 mice, 6–8 weeks, 22–25 g
Reported limits: No pharmacokinetic or therapeutic post-injury dosing evaluation; outcome sample sizes differ from randomized group size.
Vehicle / liver injury
Model: Male C57BL/6 mice, 6–8 weeks, 22–25 g
Reported limits: No pharmacokinetic or therapeutic post-injury dosing evaluation; outcome sample sizes differ from randomized group size.
Morin hydrate / liver injury
Model: Male C57BL/6 mice, 6–8 weeks, 22–25 g
Reported limits: No pharmacokinetic or therapeutic post-injury dosing evaluation; outcome sample sizes differ from randomized group size.
Methods and source locations

Compound reported in the paper: Morin hydrate; Compound label in the paper: MH

Reported effects of morin hydrate in this experimental model; no validation of an Adooq lot or conversion to anhydrous morin.

Animals and Experimental Design; Figure 1B–E; serum enzyme and histopathology methods; liver-injury Results subsection

Serum ALT and AST after liver injury: Commercial serum enzyme activity assays (U/L); mean ± SEM, n = 6 per group. Exact bar heights were not transcribed. — Results, Effect of MH on CCl4-Induced Liver Injury; Figure 1C and caption; Assay for Serum AST and ALT Levels

Hepatic necrosis: H&E; blinded pathologist; semiquantitative 0–3 scale; n = 8 per group; mean ± SEM under general statistics convention. — Figure 1D,E and caption; Analysis of Liver Histopathology

Vehicle / oil · Animals and Experimental Design; Figure 1B–E and caption

Morin hydrate / oil · Animals and Experimental Design; Figure 1B–E and caption

Vehicle / liver injury · Animals and Experimental Design; Figure 1B–E and caption

Morin hydrate / liver injury · Animals and Experimental Design; Figure 1B–E and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 6202-27-3
Alternate CAS 654055-01-3
Formula C15H12O8
Molecular Weight 320.3
SMILES
C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O.O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 54 mg/mL (168.62 mM)
Water Insoluble
Ethanol Warmed: 2 mg/mL (6.24 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Harris Noor, Ping Cao, Daniel P Raleigh. Morin hydrate inhibits amyloid formation by islet amyloid polypeptide and disaggregates amyloid fibers Protein Science : A Publication of the Protein Society (2012). PMID: 22238175 DOI: 10.1002/pro.2023 Source material
  2. [2] Chih-Wei Hsia, Ming-Ping Wu, Marappan Velusamy, et al. Novel Therapeutic Agent against Platelet Activation In Vitro and Arterial Thrombosis In Vivo by Morin Hydrate International Journal of Molecular Sciences (2018). PMID: 30104547 DOI: 10.3390/ijms19082386 Source material
  3. [3] Xi Li, Qunyan Yao, Jiying Huang, et al. Morin Hydrate Inhibits TREM-1/TLR4-Mediated Inflammatory Response in Macrophages and Protects Against Carbon Tetrachloride-Induced Acute Liver Injury in Mice Frontiers in Pharmacology (2019). PMID: 31616301 DOI: 10.3389/fphar.2019.01089 Source material

Added to your cart

View Cart Checkout
Loading...